Jordyn Sava

Patients with hormone receptor-positive endometrial cancer had an objective response rate of 30%, including 8 confirmed responses, when treated with letrozole with abemaciclib.

Data from the phase 2 MonumenTAL-1 study support the accelerated approval of talquetamab in patients with relapsed/refractory who have received at least 4 prior lines of therapy.

In an interview with Targeted Oncology, Hun Ju Lee, MD, discussed the encouraging responses shown with the combination of zilovertamab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia, and highlighted other studies making headway in the field.

Lisaftoclax is a novel, orally administered small-molecule BCL-2 selective inhibitor. A study of the agent in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma will commence in the second half of 2023.

The phase 2b VIRAGE study evaluating the combination of VCN-01 with standard-of-care chemotherapy in patients with pancreatic cancer remains on track to be fully-enrolled in the first quarter of 2024.

Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.

Though chimeric antigen receptor T cells are showing promise in T-cell acute lymphoblastic leukemia, challenges, including those related to manufacture, those that are patient/disease specific, and those regarding risk mitigation, remain a struggle.

During an interview with Targeted Oncology, Matthew A. Powell, MD, discussed the significance of the FDA approval and his presentation of the results from the RUBY trial.

There was no difference in the risk of disease progression or death outcomes noted between patients with ovarian cancer treated with batiraxcept and paclitaxel vs batiraxcept alone in the AXLerate-OC trial.

Findings from a phase 3 trial published in JAMA Oncology suggest allo-HCT may not provide an OS benefit for patients with intermediate-risk acute myeloid leukemia during first complete remission.

Despite a favorable vote by the Oncologic Drugs Advisory Committee, the FDA has opted not to approve remestemcel-L for the treatment of pediatric steroid-refractory acute graft-vs-host disease.

ABM-1310 is a novel small molecule BRAF inhibitor that has shown promising anti-cancer activity and a good safety profile across a variety of advanced BRAF V600-mutant solid tumors.

Trifluridine/tipiracil plus bevacizumab improved rates of progression-free and overall survival vs trifluridine/tipiracil alone in the SUNLIGHT study. Now, the combination is FDA-approved for patients with metastatic colorectal cancer.

The phase 1 study is evaluating the combination of a CD19-targeting chimeric antigen receptor and an orthogonal IL-2 in patients with CD19-positive hematologic malignancies.

A promising disease control rate and overall response rate was seen with elraglusib when given with chemotherapy for patients with pancreatic cancer, according to phase 2 study findings.

In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed real-world findings from a trial evaluating second-line maintenance niraparib in patients with recurrent ovarian cancer.

IVS-3001, a chimeric antigen receptor therapy developed to target and kill HLA-G-bearing cells, is currently in late-stage preclinical development for the treatment of solid tumors.

KEYNOTE-756 is the first positive phase 3 study to generate a statistically significant improvement in pathological complete response rate with an immunotherapy regimen in the neoadjuvant setting for ER-positive/HER2-negative breast cancer.

Although no safety or efficacy issues were reported in the biologics license application for denileukin diftitox for cutaneous T-cell lymphoma, a complete response letter has been issued.

The phase 3 QuANTUM-First trial showed that quizartinib plus chemotherapy with or without allogeneic hematopoietic stem cell transplant improved overall survival in patients with acute myeloid leukemia with a FLT3-ITD mutation.

ctDNA sequencing can efficiently detect KIT/PDGFRA mutations and predict outcomes in patients with tyrosine kinase inhibitor-resistant gastrointestinal stromal tumor treated with avapritinib.

Topline data from the phase 3 ATLAS and ENVISION trials of UGN-102 showed a robust and consistent therapeutic profile when used for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer.

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted pet imaging agent in prostate cancer. The agent has now been added to the NCCN guidelines.

According to data from the primary and updated analyses of the phase 2 DESTINY-Gastric02 study, trastuzumab deruxtecan is beneficial for patients with HER2-positive advanced gastric cancer.

Niraparib as a monotherapy is supported as standard of care for a broad patient population with advanced ovarian cancer after first-line platinum-based chemotherapy.

Investigators do not believe the benefit-risk profile of Lonca R in previously untreated diffuse large B-cell lymphoma supports continuation of the LOTIS-9 trial.

Investigators are evaluating the efficacy and safety of selinexor vs placebo when used as a maintenance therapy for patients with p53 wild-type advanced or recurrent endometrial cancer.

Significant progression-free survival and overall survival benefits were demonstrated with rivoceranib plus camrelizumab for patients with unresectable hepatocellular carcinoma when used in the first-line setting.

Though the benefit of consolidative stem cell transplant for patients who received A+CHP appeared less pronounced vs those treated with the CHOP regimen, the method is still supported for patients with CD30-positive peripheral T-cell lymphomas.

In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.